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Abstract  
The precise association between bronchiolitis and predisposition to childhood wheeze is 
unclear.  We assessed bronchiolitis aetiology and later wheeze phenotypes in the entire 
2007 English birth cohort.  All infants admitted to hospital in England during their first year of 
life with bronchiolitis or urinary tract infection (UTI) were followed using Hospital Episode 
Statistics, to determine risk and characteristics of wheeze admission over the subsequent 8 
years. In our cohort of 21,272 children compared to UTI, the risk of wheeze admission was 
higher with previous bronchiolitis (RR2.4), even higher in those with non-RSV bronchiolitis 
(RR3.1) and persisted into late-onset wheeze (RR1.7).
  
Introduction 1 
Bronchiolitis is the commonest reason for hospital admission in infancy.  In the UK, currently four 2 
percent of the children born per year are admitted to hospital with bronchiolitis (40.4/1000).[1]  3 
Wheeze is one of the commonest causes for admission in later childhood – 3.1 admissions / 1000 4 
children in 2016.[2]  These two respiratory diagnoses combined represent a significant burden for 5 
both children, their families and the health service.[3]  The link between respiratory syncytial virus 6 
(RSV) bronchiolitis and early (post bronchiolitis) wheeze is recognised, however the association with 7 
late phenotypes of wheeze and other viruses is less clear.[4]  With potential vaccines and 8 
therapeutic agents in development against RSV; accurately quantifying any potentially causal link 9 
could be of use for their health economic assessment.  In this study we sought to characterise the 10 
association between different viral causes of bronchiolitis and phenotypes of childhood wheeze. 11 
Method 12 
Hospital Episode Statistics discharge codes were used to create two cohorts; all infants (<12m of 13 
age) admitted to hospital in England during 2007 diagnosed with bronchiolitis or as a comparator 14 
with a urinary tract infection (UTI - chosen as the commonest non-respiratory cause for infant 15 
admission to hospital). [2]  Our case definition of bronchiolitis was children <12 months of age 16 
admitted to hospital with a clinician diagnosis of bronchiolitis (table 1). The all-cause bronchiolitis 17 
(acBr) cohort was subdivided by coded causative organism (RSV, non RSV (nRSV) or un-specified 18 
bronchiolitis (usBr)).  Patients with both diagnoses during the first year of life were excluded as were 19 
all those who had been admitted to neonatal intensive care at birth (due to an increased risk of 20 
chronic lung disease).  From their first birthday we compared the number and pattern of admissions 21 
with wheeze between the two cohorts over the subsequent eight years. Timings of recurrent 22 
wheeze episodes were used to categorise patients into previously described wheeze phenotypes.[5]  23 
To test for confounding between our cohorts we compared the rates of head injury (a common non-24 
infective reason for paediatric admission) as a negative control, with the hypothesis that if unbiased 25 
that this should not differ between cohorts.[6] R v3.4.1 was used for data cleaning and to perform 26 
log-binomial regression adjusted for gender to calculate relative risks.   27 
Results 28 
From the 2007 birth cohort of 642,000 children, we identified 17,946 cases of bronchiolitis and 3,326 29 
of UTI (Table 1) with risks of later admission with any wheeze of 19% & 7 % respectively; RR of 30 
admission 2.4 ( 95%CI 2.2-2.8). As there was a significant difference in gender between the cohorts,  31 
60% male in bronchiolitis vs 48% male in UTI we adjusted for gender in our models. Our negative 32 
control suggested no bias with no difference found in the risk of head injury admission (RR 0.96, 33 
95%CI 0.7-1.3) between the cohorts. 34 
  
Against all cause wheeze admissions, nRSV bronchiolitis had a significantly stronger association RR 35 
3.1(2.4-3.9) than for RSV RR 2.3 (2.0-2.6) p=0.01 but not the undifferentiated usBr RR 2.5 (2.2-2.8) 36 
p=0.06.  Using length of bronchiolitis admission as a proxy for disease severity there was an apparent 37 
dose effect, with risk of later wheeze increased with admissions <24hrs and steadily increasing for 38 
longer admissions (table 2).  All cause bronchiolitis increased the risk of all phenotypes of wheeze, 39 
particularly Transient, Persistent Early and Persistent. (Table 3) 40 
Discussion. 41 
We have shown that significantly more cases of all phenotypes of wheeze occur in children that have 42 
had bronchiolitis in infancy compared to those who had a UTI, with the largest effects seen in long 43 
admissions with non-RSV bronchiolitis.  This effect is most marked for the early wheeze phenotypes 44 
but persists for even late onset wheeze. 45 
Whilst the link between RSV bronchiolitis and later respiratory pathology has been consistently 46 
demonstrated, the strength and details of the association vary between populations and has not 47 
been previously described in a UK cohort.[7]  Studies have also linked rhinovirus, human meta-48 
pneumovirus and parainfluenzae as associated with later wheeze, with some suggesting a stronger 49 
effect for non-RSV bronchiolitis.[8]  The strongest form of evidence for assessing the association 50 
between bronchiolitis and wheeze is from randomised controlled trials (RCT) of monoclonal 51 
antibodies against RSV.  The Dutch MAKI RCT of Paluvizumab in premature infants found at 6 years 52 
there was a significant reduction in parentally reported wheeze (11.6% vs 19.9%) but not in 53 
physician diagnosed (10.3% vs 9.9%), concluding that there was no clinically significant effect.[9]  54 
The phase 3 RCT of Motavizumab in 2170 term Navajo infants found an 87% relative reduction in 55 
RSV related admissions but no effect on rates of medically attended wheezing (14·9% vs 14·0%) 56 
during 1–3 years follow-up.[10]  In our cohorts rates of bronchiolitis associated late onset wheeze 57 
were low (5% vs 3%); raising the possibility that with <1000 patients per arm and only a subset of 58 
these developing bronchiolitis, these trials were not adequately powered to detect this difference.  59 
Although a small percentage change, we would argue that on a population scale a vaccine that 60 
prevented any cases of a chronic health condition such as asthma as a secondary gain would be 61 
significant. 62 
The strengths of this paper are that it follows a whole English population birth cohort of 642,000 63 
children over an 8 year period.  Using a hard outcome of admission rather than parentally reported 64 
or clinician diagnosed wheeze it characterises the burden of admissions due to different phenotypes 65 
of wheeze.  Our primary analysis using all diagnostic fields found similar frequencies of wheezing 66 
during admission as in parentally reported community surveys,[11] restricting analysis to the 67 
  
primary diagnostic code found reduced incidence of wheeze (7.8% post bronchiolitis vs 3.1% post 68 
UTI) but with a similar risk ratio 2.4 (2.0-3.0) between the groups.  Its limitations are that it is reliant 69 
on quality of diagnostic coding, rates of routine virological testing and could not assess the effects on 70 
mild non-admitted wheeze presentations. As a retrospective analysis of routine health data we were 71 
not able to distinguish between different syndromic phenotypes of bronchiolitis as our dataset 72 
limited us to identifying patients by diagnostic clinical coding. Rates of routine virological testing 73 
carried out in the UK in 2007 meant we could only meaningfully compare RSV to non-RSV subgroups. 74 
Our cohort of hospitalised children represent a severe subgroup and thus our findings are likely to 75 
be an overestimate of true population effect. Our analysis was controlled for gender, in a sensitivity 76 
analysis we also included the Index of Multiple Deprivations but this did not alter the relative risk 77 
estimates.  There may be other biases that we were not able to identify.  Fundamentally as an 78 
observational study design we cannot hope to prove causality and must be cautious that our findings 79 
are not a product of the phenotype categorisation.[12] 80 
Whilst the narrative that bronchiolitis leads to an inflammatory state, the start of the allergic march 81 
and predisposition to later wheeze is appealing; that all causes of bronchiolitis are associated with all 82 
phenotypes of wheeze suggests this interpretation is actually the cart leading the horse.  Perhaps 83 
bronchiolitis is simply a marker of children who are likely to go on to wheeze in later life and 84 
represents the sentinel manifestation of those genetically or environmentally pre-disposed to 85 
wheeze.  That the association for early wheeze is stronger implies that this is more complicated than 86 
the revealing of an innate state. It may be that different clinical phenotypes of bronchiolitis[13] 87 
would be helpful in this prognostication but we were not able to assess this using this dataset. 88 
Fundamentally these data highlight our inability to prospectively clinically distinguish between 89 
wheeze phenotypes.  It is reassuring that 80% of children with even severe bronchiolitis do not go on 90 
to wheeze. Academic interest aside, the reason for this study is to be able to answer parents’ 91 
questions of “will this happen again?”  Although these data cannot elucidate the cause, they are 92 
helpful to describe likely respiratory trajectories for children.  We now plan to expand this research 93 
by also examining wheeze attendances in the emergency department and primary care to see if the 94 
association still holds for the less severe cases of bronchiolitis. 95 
HES data statement – The School of Social and Community Medicine (SSCM), University of Bristol, 96 
has a Data Sharing Agreement (DSA; NIC-1785-X7K1V) with the HSCIC for HES Admitted Patient Care 97 
(inpatient / day case) data for the financial years 2005/6 to 2014/15. The purchase of these data was 98 
funded by NIHR CLAHRC West. Copyright © 2018, re-used with the permission of The Health & Social 99 
Care Information Centre. All rights reserved.  Our data access agreement with HSIC does not allow 100 
  
distribution of source data but extraction and analysis scripts are available on request.  This work 101 
uses data provided by patients and collected by the NHS as part of their care and support and would 102 
not have been possible without access to this data. The NIHR recognises and values the role of 103 
patient data, securely accessed and stored, both in underpinning and leading to improvements in 104 
research and care. 105 
  106 
  
Tables 107 
Groups Number ICD-10 codes  
Bronchiolitis 
(60% male) 
RSV 4399 J12.1, J21.0,  
Non-RSV 
243 
J12.0, J12.2, J12.3, J12.8, 
J21.1, J21.8,  
Unspecified 13304 J12.9, J21.9 
UTI (control) (52% male) 3326 N39.0  
Outcomes 
Wheezing  4472 J45.*, J46*,R06.2  
Head Injury 325 S09* 
Excluded: 
Neonatal admissions 4654 n/a 
Both diagnoses 191 n/a 
Table 1 – Size of cohorts and defining ICD10 codes. 108 
 109 
Length of admission (days) 0 1->3 4->6 7-13 >14 Combined 
All Bronchiolitis RR (95% CI) 
2.16 
(1.9-2.5) 
2.37 
(2.1-2.7) 
2.57 
(2.3-2.9) 
3.37 
(2.9-3.9) 
3.24 
(2.4-4.3) 
2.4 
(2.2-2.8) 
RSV RR (95% CI) 
1.6 
(1.2-2.2) 
2.0 
(1.7-2.4) 
2.3 
(1.7-2.4) 
3.1 
(2.6-3.7) 
2.9 
(1.8-4.2) 
2.3 
(2.0-2.6) 
nRSV RR (95% CI) 
2.5 
(0.8-5.2) 
1.5 
(0.7-2.6) 
3.5 
2.3-4.9) 
5 
(3.3-7.0) 
3.6 
(1.4-6.6) 
3.1 
(2.4-4.0) 
usBR RR (95% CI) 
2.2 
(1.9-2.5) 
2.5 
2.2-2.8) 
2.7 
(2.4-3.1) 
3.5 
(2.9-4.3) 
3.7 
(2.3-5.5) 
2.5 
(2.2-2.8) 
Table 2 –risk ratio of later admission with wheeze by aetiology and length of bronchiolitis admission. 110 
 111 
Wheeze 
All 
Wheeze 
Phenotype 
NEVER TREY PEEY INTER LATE PRST 
Bronchiolitis 18.7% 80.1% 4.4% 0.8% 7.6% 5.0% 1.0% 
UTI 7.2% 90.4% 0.9% 0.2% 3.1% 3.1% 0.2% 
RR 2.43 n/a 5.4 4.8 2.6 1.7 5.2 
95% CI 
2.2-2.8 
n/a 3.8-8.0 
2.3-
12.1 
2.1-3.1 1.4-2.1 
2.6-
12.2 
Table 3 - Distribution of wheeze phenotypes for different cohorts and resulting risk ratios. 112 
(Phenotypes: NEVER - no wheeze; 113 
TREY - Transient early, wheeze before 18m until 42m; 114 
PEEY – Prolonged Early, wheeze before 18 until 69m; 115 
INTER – Intermediate, no wheeze until after 42m; 116 
LATE – Late onset, no wheeze until after 69m;  117 
  
PRST – Persistent, wheeze before 18m until >69m 118 
) [5] 119 
 120 
Contribution 121 
RM study design, analysis and authorship of first draft.  AF, JH critically appraised and 122 
developed the manuscript. 123 
 124 
Funding 125 
RM is funded by the NIHR as an Academic Clinical Lecturer and is a member of the NIHR 126 
Health Protection Research Unit in Evaluation of Interventions at University of Bristol. 127 
Competing Interests 128 
No competing interests 129 
Exclusive licence 130 
The Corresponding Author has the right to grant on behalf of all authors and does grant on 131 
behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a 132 
worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if 133 
accepted) to be published in Thorax and any other BMJPGL products to exploit all subsidiary 134 
rights, as set out in our licence http://journals.bmj.com/site/authors/editorial-135 
policies.xhtml#copyright and the Corresponding Author accepts and understands that any 136 
supply made under these terms is made by BMJPGL to the Corresponding Author. Where 137 
the Corresponding Author wishes to make the article available on an open access basis (and 138 
intends to pay the relevant open access fee), the terms of such open access shall be 139 
governed by a Creative Commons licence – details of these licences and which Creative 140 
Commons licence will apply to this article are set out in our licence referred to above.   141 
I confirm this manuscript has not been accepted for publication elsewhere, is not being 142 
considered for publication elsewhere and does not duplicate material already published. I 143 
confirm all authors consent to publication of this manuscript.   144 
  
References 145 
1  Green CA, Yeates D, Goldacre A, et al. Admission to hospital for bronchiolitis in England: trends 146 
over five decades, geographical variation and association with perinatal characteristics and 147 
subsequent asthma. Arch Dis Child 2016;101:140–6. doi:10.1136/archdischild-2015-308723 148 
2  Hospital Admitted Patient Care Activity, 2016-17. NHS Digit. https://digital.nhs.uk/data-and-149 
information/publications/statistical/hospital-admitted-patient-care-activity/2016-17 (accessed 23 150 
Aug 2018). 151 
3  Stevens CA, Turner D, Kuehni CE, et al. The economic impact of preschool asthma and wheeze. 152 
Eur Respir J 2003;21:1000–6. doi:10/cdvfdw 153 
4  Régnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and 154 
respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J 2013;32:820–6. 155 
doi:10.1097/INF.0b013e31829061e8 156 
5  Henderson J, Granell R, Heron J, et al. Associations of wheezing phenotypes in the first 6 years of 157 
life with atopy, lung function and airway responsiveness in mid-childhood. Thorax 2008;63:974–158 
80. doi:10.1136/thx.2007.093187 159 
6  Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding 160 
and bias in observational studies. Epidemiol Camb Mass 2010;21:383–8. doi:10/drzms4 161 
7  Fauroux B, Simões EAF, Checchia PA, et al. The Burden and Long-term Respiratory Morbidity 162 
Associated with Respiratory Syncytial Virus Infection in Early Childhood. Infect Dis Ther 163 
2017;6:173–97. doi:10/gc4ng9 164 
8  Koponen P, Helminen M, Paassilta M, et al. Preschool asthma after bronchiolitis in infancy. Eur 165 
Respir J 2012;39:76–80. doi:10/c74d4n 166 
9  Mochizuki H, Kusuda S, Okada K, et al. Palivizumab Prophylaxis in Preterm Infants and Subsequent 167 
Recurrent Wheezing. Six-Year Follow-up Study. Am J Respir Crit Care Med 2017;196:29–38. 168 
doi:10/gbmg6t 169 
10  O’Brien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of 170 
respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised 171 
double-blind placebo-controlled trial. Lancet Infect Dis 2015;15:1398–408. doi:10.1016/S1473-172 
3099(15)00247-9 173 
11  Kuehni CE, Strippoli M-PF, Low N, et al. Wheeze and asthma prevalence and related health-174 
service use in white and south Asian pre-schoolchildren in the United Kingdom. Clin Exp Allergy J 175 
Br Soc Allergy Clin Immunol 2007;37:1738–46. doi:10/fvx6d2 176 
12  Richiardi L, Barone-Adesi F, Pearce N. Cancer subtypes in aetiological research. Eur J 177 
Epidemiol 2017;32:353–61. doi:10.1007/s10654-017-0253-z 178 
13  Dumas O, Mansbach JM, Jartti T, et al. A clustering approach to identify severe bronchiolitis 179 
profiles in children. Thorax 2016;71:712–8. doi:10.1136/thoraxjnl-2016-208535 180 
 181 
